Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00621959 · ClinicalTrials.gov registry record · Phase 4
A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis
A Phase 4 study of Seasonal Allergic Rhinitis, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 4
- Development phase
- 596
- Enrollment target
- 20
- Study locations
NCT00621959: Completed Phase 4 study of Seasonal Allergic Rhinitis, sponsored by UCB Pharma.
NCT00621959 is a Phase 4 study of Seasonal Allergic Rhinitis that has completed, run by UCB Pharma. The registered enrollment target is 596 participants, roughly in line with the 631-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target. The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00621959, a Phase 4 study of Seasonal Allergic Rhinitis, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 596 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study objective is to investigate the efficacy of levocetirizine in reducing symptoms associated with seasonal allergic rhinitis and in improving rhinitis-related Quality of Life
Primary Outcome
Total 5 Symptoms Score (T5SS) is the sum of rhinorrhea, sneezing, nasal congestion, itchy nose and itchy eyes scores. Each individual symptom was scored from 0 (none) to 3 (severe). The total score varies from 0 to 15.
Conditions Studied
Interventions
- DRUG placebo
- DRUG levocetirizine dihydrochloride
Study Locations (20)
California
- - Huntington Beach
- - Long Beach
- - Los Angeles
- - Mission Viejo
Texas
- - Austin
- - Dallas
- - El Paso
- - Fort Worth
Georgia
- - Albany
- - Lilburn
- - Savannah
Arkansas
- - Hot Springs
- - Little Rock
Arizona
- - Scottsdale
Kentucky
- - Owensboro
Louisiana
- - Metairie
North Carolina
- - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 596 participants |
| Start Date | 2008-03 |
| Est. Completion | 2008-06 |
| Phase | Phase 4 |
What the finished NCT00621959 record still lists
NCT00621959 is an interventional study that assigns participants to a tested intervention. The registered 596 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 631-participant average among 16 other Seasonal Allergic Rhinitis trials with a reported enrollment target.
The record links to 1 condition, with Seasonal Allergic Rhinitis appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT00621959 names 20 study sites across 11 states, led by California, Texas, Georgia.
Frequently Asked Questions
What is clinical trial NCT00621959 about?
NCT00621959 is a clinical study titled "A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis". The study objective is to investigate the efficacy of levocetirizine in reducing symptoms associated with seasonal allergic rhinitis and in improving rhinitis-related Quality of Life
What is the current status of trial NCT00621959?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 596 participants. The study started on 2008-03. Estimated completion is 2008-06.
What conditions does trial NCT00621959 study?
This clinical trial studies the following conditions: Seasonal Allergic Rhinitis.
What interventions are being tested in trial NCT00621959?
The interventions under investigation include: placebo (DRUG), levocetirizine dihydrochloride (DRUG).
Who is sponsoring clinical trial NCT00621959?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00621959 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seasonal Allergic Rhinitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00621959's enrollment target sits among peer trials
596 9th of 16 higher than 8 of 16 other Seasonal Allergic Rhinitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Seasonal Allergic Rhinitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Comparison of Olopatadine 0.6% and Fluticasone Proprionate 50mcg Nasal Sprays in a Two Week Seasonal Allergic Rhinitis Trial
COMPLETED · Phase 4
-
Single-Center, Double-Blind, Randomized , Parallel Study Comparing Onset of Action, Efficacy & Safety of a Single-Dose of Fexofenadine HCl 180 mg vs Montelukast Na 10 mg & Placebo in Treating Seasonal Allergic Rhinitis Subjects in an Allergen Exposure Unit
COMPLETED · Phase 4
-
Intranasal Steroids and the Nasal Ocular Response
COMPLETED · Phase 4
-
Comparison of Seasonal Allergic Rhinitis Treatment With 2 Antihistamines Used in Combination With Intranasal Corticosteroid
COMPLETED · Phase 4
-
A Study Evaluating the Efficacy and Impact on Health-related Quality of Life of Levocetirizine in Adults With Seasonal Allergic Rhinitis
COMPLETED · Phase 4
-
Efficacy and Safety of Fixed Dose Combination GSP 301 Nasal Spray (NS) in the Treatment of Seasonal Allergic Rhinitis (SAR)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02138734 · 596 participants · Phase 1
A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer
- NCT06797245 · 596 participants · NA
APPROVE Trial: Evaluating a Prescription Digital Therapeutic for Treatment of OAB in Women
- NCT07100080 · 596 participants · Phase 2
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
- NCT05723198 · 595 participants · Phase 3
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia